SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 1,461.3% in July

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 9,524 shares, a growth of 1,461.3% from the June 30th total of 610 shares. Based on an average daily volume of 264,901 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Down 17.1%

NASDAQ:SABSW traded down $0.00 during mid-day trading on Friday, reaching $0.01. The company’s stock had a trading volume of 9,797 shares, compared to its average volume of 50,304. The company’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.02. SAB Biotherapeutics has a twelve month low of $0.01 and a twelve month high of $0.06.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.